Halozyme Therapeutics | HALO - Assets


Halozyme Therapeutics reported $2.53B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.56B 233.42M Dec/2025
Agios Pharmaceuticals USD 1.3B 88.48M Dec/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Amarin USD 659.81M 10.31M Sep/2025
Amgen USD 90.59B 445M Dec/2025
Baxter International USD 20.06B 1.01B Dec/2025
Cara Therapeutics USD 43.75M 4.8M Jun/2025
Cytokinetics USD 1.42B 12.02M Dec/2025
DBV Technologies USD 110.49M 32.93M Sep/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Esperion Therapeutics USD 465.89M 101.87M Dec/2025
Halozyme Therapeutics USD 2.53B 304.09M Dec/2025
Intrexon USD 73.16M 77.88M Jun/2024
Ionis Pharmaceuticals USD 3.52B 490.91M Dec/2025
MannKind USD 792.18M 297.54M Dec/2025
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Nektar Therapeutics USD 301.35M 93.81M Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
United Therapeutics USD 7.88B 528.9M Dec/2025
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025